187 related articles for article (PubMed ID: 31082509)
1. Selection of the optimal macrocyclic chelators for labeling with
von Witting E; Garousi J; Lindbo S; Vorobyeva A; Altai M; Oroujeni M; Mitran B; Orlova A; Hober S; Tolmachev V
Eur J Pharm Biopharm; 2019 Jul; 140():109-120. PubMed ID: 31082509
[TBL] [Abstract][Full Text] [Related]
2. Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with
Lindbo S; Garousi J; Mitran B; Vorobyeva A; Oroujeni M; Orlova A; Hober S; Tolmachev V
Mol Pharm; 2018 Jul; 15(7):2674-2683. PubMed ID: 29865791
[TBL] [Abstract][Full Text] [Related]
3. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
[TBL] [Abstract][Full Text] [Related]
4. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.
Lindbo S; Garousi J; Mitran B; Altai M; Buijs J; Orlova A; Hober S; Tolmachev V
J Nucl Med; 2018 Jan; 59(1):93-99. PubMed ID: 28864631
[TBL] [Abstract][Full Text] [Related]
5. Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6.
Garousi J; Lindbo S; Honarvar H; Velletta J; Mitran B; Altai M; Orlova A; Tolmachev V; Hober S
Bioconjug Chem; 2016 Nov; 27(11):2678-2688. PubMed ID: 27740752
[TBL] [Abstract][Full Text] [Related]
6. Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts.
Strand J; Honarvar H; Perols A; Orlova A; Selvaraju RK; Karlström AE; Tolmachev V
PLoS One; 2013; 8(8):e70028. PubMed ID: 23936372
[TBL] [Abstract][Full Text] [Related]
7. Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA.
Altai M; Strand J; Rosik D; Selvaraju RK; Eriksson Karlström A; Orlova A; Tolmachev V
Bioconjug Chem; 2013 Jun; 24(6):1102-9. PubMed ID: 23705574
[TBL] [Abstract][Full Text] [Related]
8. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.
Roosenburg S; Laverman P; Joosten L; Cooper MS; Kolenc-Peitl PK; Foster JM; Hudson C; Leyton J; Burnet J; Oyen WJ; Blower PJ; Mather SJ; Boerman OC; Sosabowski JK
Mol Pharm; 2014 Nov; 11(11):3930-7. PubMed ID: 24992368
[TBL] [Abstract][Full Text] [Related]
9. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours.
Garousi J; Lindbo S; Borin J; von Witting E; Vorobyeva A; Oroujeni M; Mitran B; Orlova A; Buijs J; Tolmachev V; Hober S
Eur J Pharm Biopharm; 2019 Jan; 134():37-48. PubMed ID: 30408518
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
Malmberg J; Perols A; Varasteh Z; Altai M; Braun A; Sandström M; Garske U; Tolmachev V; Orlova A; Karlström AE
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):481-92. PubMed ID: 22322933
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m.
Garousi J; Lindbo S; Mitran B; Buijs J; Vorobyeva A; Orlova A; Tolmachev V; Hober S
Sci Rep; 2017 Nov; 7(1):14780. PubMed ID: 29116215
[TBL] [Abstract][Full Text] [Related]
13. ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers.
Garousi J; Lindbo S; Nilvebrant J; Åstrand M; Buijs J; Sandström M; Honarvar H; Orlova A; Tolmachev V; Hober S
Cancer Res; 2015 Oct; 75(20):4364-71. PubMed ID: 26297736
[TBL] [Abstract][Full Text] [Related]
14. Increase in negative charge of
Rinne SS; Dahlsson Leitao C; Gentry J; Mitran B; Abouzayed A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Nov; 9(1):17710. PubMed ID: 31776413
[TBL] [Abstract][Full Text] [Related]
15. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
Mitran B; Varasteh Z; Selvaraju RK; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Rosenström U; Orlova A
Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
Altai M; Perols A; Karlström AE; Sandström M; Boschetti F; Orlova A; Tolmachev V
Nucl Med Biol; 2012 May; 39(4):518-29. PubMed ID: 22172396
[TBL] [Abstract][Full Text] [Related]
17. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
18. Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.
Rinne SS; Dahlsson Leitao C; Saleh-Nihad Z; Mitran B; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183096
[TBL] [Abstract][Full Text] [Related]
19. Phase I Study of
Bragina O; von Witting E; Garousi J; Zelchan R; Sandström M; Orlova A; Medvedeva A; Doroshenko A; Vorobyeva A; Lindbo S; Borin J; Tarabanovskaya N; Sörensen J; Hober S; Chernov V; Tolmachev V
J Nucl Med; 2021 Apr; 62(4):493-499. PubMed ID: 32817142
[TBL] [Abstract][Full Text] [Related]
20. Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of
Dahlsson Leitao C; Rinne SS; Mitran B; Vorobyeva A; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30832342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
